MedTrace Logo

Evaluation of ETC-1907206 With Dasatinib in Advanced Haematologic Malignancies

NCT03414450 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2018-10-25

No results posted yet for this study

Summary

This study evaluates the use of ETC-1907206 in combination with dasatinib in certain types of blood cancers. The first phase of the study (1A) is designed to find the highest tolerated dose of ETC-1907206, while the second phase (1B) will assess the safety and tolerability of the recommended dose of ETC-1907206. ETC-1907206 has been designed to block the activity of an enzyme of the body known as Mnk kinase, which is thought to be involved in the development of a variety of cancers.

Conditions

  • Ph+ Acute Lymphoblastic Leukemia (Ph+ALL)
  • Ph- Acute Lymphoblastic Leukemia (Ph-ALL)
  • Chronic Myeloid Leukemia Accelerated Phase (CML-AP, Ph+)
  • Chronic Myeloid Leukemia Blast Crisis (CML-BC, Ph+)

Interventions

DRUG

ETC-1907206

ETC-1907206 gelatin capsules will be dosed every other day (EOD) and contain 10 mg or 50 mg of ETC-1907206.

DRUG

dasatinib

dasatinib tablets at 140 mg will be dosed every day

Sponsors & Collaborators

  • Chiltern International Inc.

    collaborator INDUSTRY

  • EDDC (Experimental Drug Development Centre), A*STAR Research Entities

    lead OTHER_GOV

Principal Investigators

  • Joel Leong, MD, PhD · D3 (Drug Discovery and Development)

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-25
Primary Completion
2022-02-28
Completion
2023-02-28
FDA Drug
Yes

Countries

  • United States
  • Singapore

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03414450 on ClinicalTrials.gov